logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
2020
Cidara Therapeutics, Inc.
Top line results from phase III pivotal clinical trial of Rezafungin(ReSPECT Prophylaxis)
Allogeneic bone marrow transplant

2020
Cidara Therapeutics, Inc.
Top-line data from phase III study of Rezafungin (ReSTORE)
modified intention-to-treat (mITT) patients with candidemia and/or invasive candidiasis
after Q1 2020
Clementia Pharmaceuticals Inc.
12-month interim data readout from phase II study of Palovarotene (MO-Ped Trial)
pediatric patients with multiple osteochondromas (MO) also known as multiple hereditary exostoses (MHE)
2020
BeyondSpring Inc.
Submission of NDA for Plinabulin
Non-small cell lung cancer (NSCLC)
Q1 2020
Savara Inc
Top-line results from phase 2a clinical study of Molgradex (OPTIMA)
Persistent pulmonary NTM infection
2020
Biogen Inc.
One-year follow-up data from phase III trial of iNSR-REP1 (STAR)
Choroideremia
after Q1 2020
Otonomy Inc.
Top-line results from phase III trial of OTIVIDEX
Ménière's disease
after Q1 2020
Idera Pharmaceuticals, Inc.
Final results from phase I/II trial of Tilsotolimod in combination with Ipilimumab(ILLUMINATE-204)
PD-1 refractory melanoma
Q1 2020
Aridis Pharmaceuticals Inc
Data from Phase I trial of AR-501
Cystic fibrosis
Q1 2020
Aridis Pharmaceuticals Inc
Interim data from phase III pivotal trial of AR-301
Acute pneumonia caused by S. aureus infection
after Q1 2020
Therapix Biosciences Ltd.
Top line results from 12-week clinical trial for THX-110
Tourette syndrome
after Q1 2020
Catalyst Pharmaceutical Partners Inc.
Top-line results from phase III MuSK-MG trial of Firdapse
Myasthenia gravis patients with autoantibodies to muscle-specific tyrosine kinase (MuSK)
after Q1 2020
Onconova Therapeutics, Inc
Top-line data from phase III pivotal trial of intravenous Rigosertib (INSPIRE)
Myelodysplastic Syndromes
after Q1 2020
Tonix Pharmaceuticals Holding Corp.
Topline data from phase III trial of Tonmya (RECOVERY)
Civilian and military-related posttraumatic stress disorder
after Q1 2020
Gamida-Cell Ltd.
Top-line data from phase III trial of NiCord
Hematologic malignancies
Q1 2020
Novan Inc.
Top line results from Phase 3 program of SB206
Molluscum
2020
Flexion Therapeutics, Inc.
Data readout from phase III study of Zilretta
Hip osteoarthritis
Early 2020
TCR2 Therapeutics
Filing of IND for TC-220
CD19-positive B-cell hematological malignancies
2020
RHYTHM PHARMACEUTICALS, INC.
Topline data from phase III trial of Setmelanotide
BBS and Alström syndrome
2020
Zealand Pharma A/S
Results from phase III trial of Glepaglutide
Short bowel syndrome
after Q1 2020
Axsome Therapeutics, Inc.
Top-line results from phase II/III trial of AXS-05 (ADVANCE-1)
Agitation associated with Alzheimer's disease
after Q1 2020
SCYNEXIS, Inc.
Top-line data from phase III VANISH program, evaluating oral Ibrexafungerp
Acute vulvovaginal candidiasis
after Q1 2020
Catalyst Pharmaceutical Partners Inc.
Top-line results from proof-of-concept phase II trial of Firdapse
Ambulatory patients with spinal muscular atrophy (SMA) type 3
2020
ChemoCentryx Inc.
Top-line data from phase II trial of Avacopan
kidney disease C3 Glomerulopathy (C3G)
Q1 2020
Blueprint Medicines
Submission of NDA for Avapritinib
Advanced systemic mastocytosis
>